N-benzyl-2-{[5,6-di(furan-2-yl)-1,2,4-triazin-3-yl]sulfanyl}acetamide

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: N-benzyl-2-{[5,6-di(furan-2-yl)-1,2,4-triazin-3-yl]sulfanyl}acetamide
• 英文别名: N-benzyl-2-[[5,6-bis(furan-2-yl)-1,2,4-triazin-3-yl]sulfanyl]acetamide
• 化学式: C₂₀H₁₆N₄O₃S
• 分子量: 392.4
• InChiKey: ZUWUIGKFBJCFIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  119
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• METHODS AND COMPOSITIONS FOR USE OF TREX2 AS DIAGNOSTIC AND PROGNOSTIC MARKER FOR CANCER
  申请人：THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20200239969A1

  公开（公告）日：2020-07-30

  Provided here are methods of assessing prognosis for a patient who has been diagnosed with a type of cancer by measuring TREX2 mRNA expression in a biological sample from the patient, comparing the TREX2 mRNA expression in the biological sample to a reference value, and providing a prognosis based on alterations in the TREX2 mRNA expression and the type of cancer. Also provided here are methods of treating a patient with myelodysplastic syndrome by administering a therapeutically effective amount of a pharmaceutical composition that decreases TREX2 mRNA expression in the patient.
• COMPOSITIONS FOR INHIBITING 3' REPAIR EXONUCLEASE 2 AND METHODS OF SCREENING FOR SUCH COMPOSITIONS
  申请人：THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20200253913A1

  公开（公告）日：2020-08-13

  Provided here are therapeutically effective pharmaceutical compositions containing one or more TREX2 inhibitors, and more specifically methods of administering TREX2 inhibitors to increase the effectiveness of a chemotherapeutic agent. Also provided here are methods of identifying agents that inhibit the exonuclease activity of TREX2.
• [EN] COMPOSITIONS FOR INHIBITING 3' REPAIR EXONUCLEASE 2 AND METHODS OF SCREENING FOR SUCH COMPOSITIONS<br/>[FR] COMPOSITIONS POUR INHIBER L'EXONUCLÉASE 2 DE RÉPARATION 3' ET PROCÉDÉS DE CRIBLAGE POUR DE TELLES COMPOSITIONS
  申请人：UNIV TEXAS

  公开号：WO2019079222A1

  公开（公告）日：2019-04-25

  Provided here are therapeutically effective pharmaceutical compositions containing one or more TREX2 inhibitors, and more specifically methods of administering TREX2 inhibitors to increase the effectiveness of a chemotherapeutic agent. Also provided here are methods of identifying agents that inhibit the exonuclease activity of TREX2.
• [EN] METHODS AND COMPOSITIONS FOR USE OF TREX2 AS DIAGNOSTIC AND PROGNOSTIC MARKER FOR CANCER<br/>[FR] PROCÉDÉS ET COMPOSITIONS DESTINÉS À L'UTILISATION DE TREX2 EN TANT QUE MARQUEUR DE DIAGNOSTIC ET DE PRONOSTIC DU CANCER
  申请人：UNIV TEXAS

  公开号：WO2019079255A1

  公开（公告）日：2019-04-25

  Provided here are methods of assessing prognosis for a patient who has been diagnosed with a type of cancer by measuring TREX2 mRNA expression in a biological sample from the patient, comparing the TREX2 mRNA expression in the biological sample to a reference value, and providing a prognosis based on alterations in the TREX2 mRNA expression and the type of cancer. Also provided here are methods of treating a patient with myelodysplastic syndrome by administering a therapeutically effective amount of a pharmaceutical composition that decreases TREX2 mRNA expression in the patient.